Clinical trial
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of…
NCT04173273 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT04173273 |
|---|---|
| Title | A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease |
| Acronym | CULTIVATE |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Arena is a wholly owned subsidiary of Pfizer Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Etrasimod, Placebo |
| Enrollment | 375 |
| Start date | Jan 6, 2020 |
| Primary completion | Apr 23, 2025 |
| Completion | Jun 9, 2025 |
| First posted | Nov 21, 2019 |
| Last update posted | Jul 16, 2025 |
| Countries | Argentina, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark and 29 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: